Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs
Increasingly Crowded Field
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.
